Systematic review of randomized controlled trials in the treatment of dry eye disease in Sjogren syndrome

Shih, Kendrick Co; Lun, Christie Nicole; Jhanji, Vishal; Thong, Bernard Yu‐Hor; Tong, Louis

doi:10.1186/s12950-017-0174-3

Cited by 41 publications

(34 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Unfortunately, no curative agents exist for SS. Therapeutic approaches include topical and systemic treatments to manage the sicca and systemic symptoms, with the aim of improving the quality of life . The long‐term prognosis of patients with pSS is unclear.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Expression of interleukin‐17 in primary Sjögren's syndrome and the correlation with disease severity: A systematic review and meta‐analysis

et al. 2018

View full text Add to dashboard Cite

The aberrant expression of interleukin-17 (IL-17) has been reported in primary Sjögren's syndrome (pSS). Abnormalities in IL-17 can promote the production of pro-inflammatory cytokines and aggravate autoimmune disorders. The aim of this study was to investigate alterations of IL-17 in patients with pSS and explore the correlation between IL-17 and disease severity. Eight databases were searched for original studies reporting the expression of IL-17 in patients with pSS and controls. Eligible reports were included in the pooled analysis, and subgroup evaluations were performed according to different types of controls and IL-17 measurement methods. Newcastle-Ottawa Scale criteria were used to assess the risk of bias of the included studies. In total, 45 articles are included in the meta-analysis. The expression of IL-17 is significantly increased in patients with pSS compared to controls. Furthermore, patients with pSS without immunosuppressive treatment show markedly higher IL-17 levels. In addition, patients with pSS with positive rheumatoid factors tend to express a higher level of IL-17 than patients with negative rheumatoid factors. Negative correlations between IL-17 levels and ocular parameters are also found in patients with pSS. The results are similar after adjustment by "trim and fill" methods. In conclusion, the expression of IL-17 is obviously increased in patients with pSS, especially among those without immunosuppressive treatment. In addition, IL-17 level correlates with the disease severity of pSS. These findings demonstrate the significance of IL-17 overexpression in patients with pSS and may provide insights for the development of therapeutic interventions targeting IL-17 for pSS.

show abstract

Section: Introductionmentioning

confidence: 99%

“…Therapeutic approaches include topical and systemic treatments to manage the sicca and systemic symptoms, with the aim of improving the quality of life. 7,8 The long-term prognosis of patients with pSS is unclear. Non-Hodgkin lymphoma (NHL) represents the most severe complication, affecting approximately 5% of patients with pSS.…”

Section: Introductionmentioning

confidence: 99%

Expression of interleukin‐17 in primary Sjögren's syndrome and the correlation with disease severity: A systematic review and meta‐analysis

et al. 2018

View full text Add to dashboard Cite

show abstract

“…While topical fluorometholone has been shown to be more effective than cyclosporine eye drops in controlling dry eye signs and symptoms in Sjögren's syndrome, the recognised and not insignificant side effects associated with corticosteroid use would favour cyclosporine as the lower‐risk clinical option for long‐term therapy.…”

Section: Effect Of Treatments For Dry Eye Diseasementioning

confidence: 99%

Molecular evidence for the role of inflammation in dry eye disease

Ganesalingam

Ismail

Sherwin

et al. 2019

Clinical and Experimental Optometry

View full text Add to dashboard Cite

Ocular surface inflammation is propagated by a complex series of molecular processes and has been implicated in the pathogenesis of dry eye disease (DED), either as a causal or a downstream effect of ocular surface disease. A state of hyperosmolarity elicits an acute immune response in DED, leading to subsequent activation of the adaptive immune response. This cascade incites dysregulation of the immune system, triggering a vicious cycle of events that causes damage to the ocular surface. Symptoms associated with these events include burning, irritation, redness, photophobia and blurred vision. The chronic nature of the disease process can cause permanent alterations to the ocular surface and adnexa. An increasing investment in treatment options, and positive outcomes with novel therapies that have received subsequent regulatory approval, lends further support to the role of inflammation in DED. This review highlights the nature and function of a range of fundamental inflammatory molecules in DED to provide the clinician with an appreciation for the ways in which these factors might be manipulated in DED management.

show abstract

“…67 Topical agents may be effective for ocular involvement in pSS; response to systemic immunosuppressive agents has been disappointing. 68…”

Section: Specific Organ Involvement Ocular/ophthalmicmentioning

confidence: 99%

Pulmonary and Bronchiolar Involvement in Sjogren's Syndrome

Chung

Wilgus

Fishbein

et al. 2019

Semin Respir Crit Care Med

View full text Add to dashboard Cite

Sjogren's syndrome (SS) is a chronic autoimmune disease characterized by mononuclear cells (principally lymphocytes) infiltrating exocrine glands (e.g., salivary and lacrimal glands), leading to destruction of exocrine epithelial cells and dryness of mucosal surfaces. Cardinal symptoms are dry eyes (xerophthalmia) and dry mouth (xerostomia). Extraglandular sites are affected in 30 to 40% of cases of SS (particularly neurological, kidneys, skin, and lungs). B cell hyperactivity, autoantibody production, and hypergammaglobulinemia are cardinal features of SS. Primary SS is not associated with other autoimmune diseases. However, SS can complicate diverse autoimmune disorders (particularly systemic lupus erythematosus, rheumatoid arthritis, and scleroderma); this form is termed “secondary SS.” Pulmonary involvement is usually not a dominant feature of SS, but may be severe in some cases. In this review, we discuss specific tracheal, bronchiolar, and pulmonary complications of SS including xerotrachea, bronchiolitis, bronchiectasis, interstitial lung disease, nonspecific interstitial pneumonia, usual interstitial pneumonia, lymphoid interstitial pneumonia, organizing pneumonia, acute fibrinous and organizing pneumonia, pulmonary cysts, pleural effusions, pulmonary amyloidosis, and bronchus- or lung-associated lymphomas.

show abstract

Systematic review of randomized controlled trials in the treatment of dry eye disease in Sjogren syndrome

Cited by 41 publications

References 50 publications

Expression of interleukin‐17 in primary Sjögren's syndrome and the correlation with disease severity: A systematic review and meta‐analysis

Expression of interleukin‐17 in primary Sjögren's syndrome and the correlation with disease severity: A systematic review and meta‐analysis

Molecular evidence for the role of inflammation in dry eye disease

Pulmonary and Bronchiolar Involvement in Sjogren's Syndrome

Contact Info

Product

Resources

About